Dov Goldstein

Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC.

Topaz Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on developing and commercializing treatments for the pediatric and dermatology markets. Its lead investigational product is a topical cream formulation of ivermectin which is under development. The firm provides medicines for the treatment of head lice, acne and infections, as well as vaccines against childhood diseases. The company was founded by Donald P. Beeman and Nicholas U. Spring in 2005 and is headquartered in Horsham, PA.

Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ.

Scerene Healthcare, Inc. had developed and delivered personal care solutions. The firm had provided anti-aging skin care and feminine protection products. It offered facial anti-aging skin care products and tampons. The company was founded in 2009 and was headquartered in Peapack, NJ.

Part of RCMA Services (UK) Ltd., RCMC Capital LLP is a private limited partnership based in London, UK. RCMC Capital is authorised and regulated by the FCA as an alternative investment fund manager and is also registered with the Commodities and Futures Trading Commission as a commodity pool operator. The British company provides general information about their services on their website, but it is not intended for public use or distribution. Investors should independently verify and check the accuracy, completeness, reliability, and suitability of the information before making any investment decision. The information contained on the webpage does not constitute financial, investment, legal, accounting, tax, or other professional advice or a solicitation for investment in RCMA's funds. The company was founded in 2004 and Douglas King has been the CEO of the company since 2004.

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.

BioAge Labs, Inc. develops biological products. It offers data with machine learning to measure human aging and accelerate drug discovery. The company was founded by Kristen Fortney and is headquartered in Berkeley, CA.

Geom Therapeutics, Inc. operates as a biotechnology company focused on the development of novel antibiotics for MDR gram-negative infections. The company is headquartered in San Francisco, CA.

Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA.

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on March 29, 2002 and is headquartered in Pittsburgh, PA.

Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX.

Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.

RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company.